These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 39340205)

  • 41. A disproportionality analysis of low molecular weight heparin in the overall population and in pregnancy women using the FDA adverse event reporting system (FAERS) database.
    Xu H; Xu N; Wang Y; Zou H; Wu S
    Front Pharmacol; 2024; 15():1442002. PubMed ID: 39188956
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Real-World Pharmacovigilance Study of Ceftazidime/Avibactam: Data Mining of the Food and Drug Administration Adverse Event Reporting System Database.
    Yao H; Wang Y; Peng Y; Huang Z; Gan G; Wang Z
    J Clin Pharmacol; 2024 Jul; 64(7):820-827. PubMed ID: 38375685
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Data mining and safety analysis of avatrombopag: a retrospective pharmacovigilance study based on the US food and drug administration's adverse event reporting system.
    Zhu H; Wu M
    Sci Rep; 2024 May; 14(1):11262. PubMed ID: 38760419
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cardiac toxicity of brentuximab vedotin: a real-word disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database.
    Ke C; Chen M; Huang Y; Chen Y; Lin C; Huang P
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Jul; 397(7):5253-5264. PubMed ID: 38270617
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA's adverse event reporting system: a case control pharmacovigilance study.
    Lin W; Zeng Y; Weng L; Yang J; Zhuang W
    BMC Pharmacol Toxicol; 2024 Aug; 25(1):47. PubMed ID: 39123221
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comprehensive evaluation of leuprorelin-associated adverse events: insights from FDA adverse event reporting system.
    Tang X; Zheng F; Ma Z; Shen H; Yao Z
    Expert Opin Drug Saf; 2024 Oct; ():1-10. PubMed ID: 39469972
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association of H1-antihistamines with torsade de pointes: a pharmacovigilance study of the food and drug administration adverse event reporting system.
    Ali Z; Ismail M; Khan F; Sajid H
    Expert Opin Drug Saf; 2021 Jan; 20(1):101-107. PubMed ID: 33141610
    [No Abstract]   [Full Text] [Related]  

  • 48. Safety assessment of basiliximab using real-world adverse event data from the FDA Adverse Event Reporting System Database: A retrospective observational study.
    Chen S; Ma X; Zhang J
    Medicine (Baltimore); 2024 Sep; 103(36):e39537. PubMed ID: 39252278
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detection and analysis of signals of adverse events of memantine based on the US food and drug administration adverse event reporting system.
    Zhang W; Chen M; Cai X; Zhang M; Hu M; Hu Y; Yang Y; Zhu J; Du Y; Yang C
    Expert Opin Drug Saf; 2024 May; 23(5):617-625. PubMed ID: 38568141
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mining of neurological adverse events associated with valbenazine: A post-marketing analysis based on FDA adverse event reporting system.
    Zhang Y; Jia X; Shi X; Chen Y; Xue M; Shen G; Wen L; Qiao Y; Yang Y
    Gen Hosp Psychiatry; 2024; 90():22-29. PubMed ID: 38901166
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System Events for Trametinib.
    Zhang X; Li R; Li Y; He L; Hou E
    Cureus; 2024 Aug; 16(8):e67925. PubMed ID: 39328691
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database.
    Liu W; Du Q; Guo Z; Ye X; Liu J
    Front Pharmacol; 2023; 14():1283247. PubMed ID: 38027003
    [No Abstract]   [Full Text] [Related]  

  • 53. Post-marketing safety concerns with abrocitinib: a real-world pharmacovigilance analysis of the FDA adverse event reporting system.
    Zhu Z; Liu M; Zhang H; Zheng H; Li J
    Expert Opin Drug Saf; 2024 May; ():1-8. PubMed ID: 38743462
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neurological and Psychiatric Adverse Events Associated with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer Patients: Insights from a Pharmacovigilance Study via the FDA Adverse Event Reporting System.
    Yu Z; Guan M; Liao X
    Clin Drug Investig; 2024 Oct; 44(10):789-798. PubMed ID: 39392584
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety evaluation of ceftazidime/avibactam based on FAERS database.
    Zhang X; Jiang Y; Guo Y; Zhou W; Qiao W; Zhu H; Qi Z
    Infection; 2024 Jun; ():. PubMed ID: 38842750
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adverse event reporting system.
    Zhao J; Tao Y
    Front Pharmacol; 2024; 15():1393940. PubMed ID: 39185318
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms.
    Sakaeda T; Kadoyama K; Minami K; Okuno Y
    Int J Med Sci; 2014; 11(5):461-5. PubMed ID: 24688309
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Real-world pharmacovigilance analysis of galsulfase: a study based on the FDA adverse event reporting system (FAERS) database.
    Li S; Huang R; Meng Y; Liu Y; Qian J; Zou J; Yang J
    Front Pharmacol; 2024; 15():1420126. PubMed ID: 39161895
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Post-marketing safety of tralokinumab: a real-world pharmacovigilance study based on the FDA adverse event reporting system.
    Yang Z; Tang K; Chen J
    Expert Opin Drug Saf; 2024 Nov; 23(11):1439-1446. PubMed ID: 39325652
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Systemic quinolones and risk of retinal detachment I: analysis of data from the US FDA adverse event reporting system.
    Taher MK; Alami A; Gravel CA; Tsui D; Bjerre LM; Momoli F; Mattison D; Krewski D
    Expert Opin Drug Saf; 2022 Feb; 21(2):269-276. PubMed ID: 34641748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.